Related Experiment Videos
Alpha 1-antitrypsin deficiency and liver disease: clinical presentation, diagnosis and treatment
M Hussain1, G Mieli-Vergani, A P Mowat
1Department of Child Health, King's College Hospital, Denmark Hill, London, UK.
Insights
Alpha 1-antitrypsin deficiency (AATD) significantly increases liver disease risk in infants and children, often leading to cirrhosis and early mortality. Early diagnosis and intervention, potentially including AAT infusions or gene therapy, are crucial for managing this genetic liver disorder.
Area of Science:
- Hepatology
- Genetics
- Pediatrics
Background:
- Alpha 1-antitrypsin deficiency (AATD), specifically the protease inhibitor (PI) phenotype ZZ, predisposes individuals to severe liver disease.
- This genetic condition manifests in infancy with conjugated hyperbilirubinemia, hepatitis, or vitamin K malabsorption-related bleeding.
- Liver cirrhosis affects 50% of affected individuals, with a 25% mortality rate within the first decade of life.
Purpose of the Study:
- To review the pathobiology of alpha 1-antitrypsin deficiency and its impact on liver damage.
- To discuss the vulnerability of the newborn liver to AATD-related injury.
- To explore potential therapeutic strategies, including AAT infusions and gene modification, for AATD liver disease.
Main Methods:
- Literature review of pathobiology, clinical manifestations, and treatment of alpha 1-antitrypsin deficiency-related liver disease.
- Discussion of diagnostic methods including isoelectric focusing and allele-specific oligonucleotide hybridization.
- Exploration of therapeutic options, including supportive care for cholestasis and cirrhosis, liver transplantation, and emerging gene therapies.
Main Results:
- AATD presents with significant risks including neonatal hepatitis, cirrhosis, and hepatoma in adults.
- Early infancy is a critical period for AATD-related liver complications.
- Current treatments focus on managing symptoms of cholestasis and cirrhosis, with liver transplantation as a definitive option.
Conclusions:
- Alpha 1-antitrypsin deficiency poses a substantial threat to liver health, particularly in early life.
- There is a need for early diagnosis and intervention trials, such as alpha 1-antitrypsin infusions in infancy.
- Gene modification presents a promising future avenue for treating the underlying cause of AATD-associated liver disease.
Abstract:
The alpha 1-antitrypsin deficient subject (protease inhibitor (PI) phenotype ZZ) has an increased susceptibility to liver disease. The condition is most commonly identified in early infancy as a conjugated hyperbilirubinaemia with hepatitis (11%) or a bleeding state due to vitamin K malabsorption (2%). 50% of cases have cirrhosis and 25% die in the first decade of life. A further 2% present with cirrhosis in later childhood. Adult males are at risk of hepatoma development with or without cirrhosis. Diagnosis is by isoelectric focussing or allele-specific oligonucleotide hybridization. The treatment is that of cholestasis and cirrhosis including transplantation. The pathobiology of the deficiency state, the mechanism of liver damage and the vulnerability of the newborn liver are discussed in this review. A plea is made for a trial of infusions of alpha 1-antitrypsin in early infancy, as is used safely but without proven efficacy in the emphysematous PIZZ subject. Prospects of therapy by gene modification are also reviewed.